News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
New Ovarian Cancer Vaccine Shows Promise
Catherine Offord | Apr 12, 2018
A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.
Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months
Catherine Offord | Dec 17, 2017
More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
The Cancer Genes Needed for Immunotherapy Response
Anna Azvolinsky | Aug 7, 2017
Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors.
Personalized Cancer Vaccines Show Promise for Melanoma
Jef Akst | Jul 6, 2017
In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse.
Gene Mutations Foretell Immunotherapy Response
Aggie Mika | Jun 12, 2017
A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes.
Hitting It Out of the Park
Mary Beth Aberlin | Apr 1, 2017
Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.
Tasmanian Devil Cancer Immunotherapy
Bob Grant | Mar 13, 2017
Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.
Kite’s CAR T-Cell Therapy Success
Jef Akst | Mar 1, 2017
More than one-third of lymphoma patients in a Phase 2 trial were clear of disease at six months, and no new safety concerns arose since the company’s three-month follow up.